RNA-binding Factors Implicated in Neurogenesis, Alzheimer's Disease, and other Neurodegenerative Pathologies

National Institute On Aging

Investigators

Linked publications & trials

Abstract

Several studies are underway in the RNA Regulation Section to investigate the gene expression programs that influence neuronal physiology and pathology, with particular emphasis on neurodegeneration. During this review period, we have studied the transcriptomic programs of senescent cells that modulate amyloid plaques in Alzheimers disease (AD). In this project area, we previously reported that the levels of amyloid precursor protein (APP), which is cleaved to release the Alzheimers disease hallmark peptide Abeta, was regulated by RBPs FMRP (fragile X mental retardation protein) and hnRNP C (heterogeneous nuclear ribonucleoprotein C) (Lee et al., Nature Structural and Molecular Biology, 2010), as well as by the RBP HuD (Kang et al., Cell Reports 2014). This earlier led us to propose that HuD jointly promotes the production of APP and the cleavage of its amyloidogenic fragment, Abeta. Work is underway to investigate the potential use of antisense oligonucleotides (ASOs) to lower HuD levels, which we hypothesize would in turn lower the levels of APP and BACE1 in human and mouse. After reporting the presence of mitochondrial RNA in Alzheimer's disease circulating extracellular vesicles (Kim et al., Frontiers in Cell and Developmental Biology, 2020), we have supported studies showing that loss of mitochondrial sirtuins (SIRT3) causes hyperexcitability of the neuronal network accelerates age-related A pathology, and sensitizes neurons to A toxicity (NeuroMolecular Medicine, 2023), and found that circular RNAs arising from synaptic host genes during human neuronal differentiation are modulated by SFPQ RNA-binding protein (BMC Biology, 2023). In collaboration with the King lab, we reviewed the impact of an RBP that we have studied for a long time, HuR, on glioblastoma, a malignancy that increases with advancing age (Advanced Drug Delivery Reviews, 2022), and reported the dysregulation circular RNAs in human ALS skeletal muscle (Aging, 2023).